Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Luminita Rusen"'
Autor:
Jerzy Windyga MD, PhD, Oleksandra Stasyshyn MD, PhD, Toshko Lissitchkov MD, PhD, Vasily Mamonov MD, PhD, Margit Serban MD, PhD, Luminita Rusen MD, PhD, Bettina Ploder MSc, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS ® ) in patients with severe or moderately severe hemophilia B. The study popu
Externí odkaz:
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7
Autor:
K. Kavakli, R. Yang, L. Rusen, H. Beckmann, D. Tseneklidou‐Stoeter, M. Maas Enriquez, Renchi Yang, Yongqiang Zhao, Jing Sun, Xuefeng Wang, Depei Wu, Antonin Hlusi, Katsuyuki Fukutake, Hideji Hanabusa, Teruhisa Fujii, Oscar Pérez Ramírez, Blanca Salazar Alvarado, Margit Serban, Luminita Rusen, Valentina Uscatescu, Cristina Truica, Gordana Kostic, Nada Konstantinidis, Zoran Igrutinovic, Farida Perina, Tatiana Andreeva, Kaan Kavakli, Bulent Antmen, Ilgen Sasmaz, Alphan Kupesiz, Mehmet Akif Yesilipek, Ching‐Tien Peng, James French, Miguel Escobar, Johnny Mahlangu, Roger Pool
Publikováno v:
Journal of Thrombosis and Haemostasis
WOS: 000350548500005
PubMed ID: 25546368
BackgroundBAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance
PubMed ID: 25546368
BackgroundBAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4eb2c95999e1df608a170f7d836b5c
https://doi.org/10.1111/jth.12828
https://doi.org/10.1111/jth.12828
Autor:
Luminita Rusen, Rafael Parra Lopez, Víctor Jiménez-Yuste, Laszlo Nemes, James Baumann, Pablo Rendo, Ana Rosa Cid, Joan M. Korth-Bradley, Robert J Charnigo, Lynne Smith
Publikováno v:
Thrombosis and Haemostasis. 114:676-684
SummaryThis prospective, open-label, postauthorisation safety surveillance study assessed clinically significant inhibitor development in patients with severe haemophilia A transitioning from moroctocog alfa or other factor VIII (FVIII) replacement p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21136c4ad65db751e452984d40512cc
https://doi.org/10.1160/th14-09-0760
https://doi.org/10.1160/th14-09-0760